U.S. FDA Grants Priority Review of New Drug Application for Gilead’s Once-Daily HIV Treatment of Bictegravir Plus Lenacapavir
Go back to U.S. FDA Grants Priority Review of New Drug Application for Gilead’s Once-Daily HIV Treatment of Bictegravir Plus Lenacapavir| Gilead Sciences (NASDAQ: GILD) | Delayed: 124.87 +1.11 (0.90%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $123.76 | 52 Week High | $108.63 | |||
| Open | $124.30 | 52 Week Low | $71.39 | |||
| Day High | $125.17 | P/E | 68.99 | |||
| Day Low | $123.00 | EPS | $1.81 | |||
| Volume | 8,126,292 | |||||
